Skip to main content

Table 5 Distribution of survey results and claims data in patient groups with and without prior discussion of the option of TJR by physician

From: Which disease-related factors influence patients’ and physicians’ willingness to consider joint replacement in hip and knee OA? Results of a questionnaire survey linked to claims data

 Symptomatic Hip OASymptomatic Knee OA
VariableTJR discussed n = 215,
44% (weighted)
TJR not discussed n = 255,
56% (weighted)
TJR discussed n = 387,
45% (weighted)
TJR not discussed n = 524,
55% (weighted)
Age (years), mean64 (62; 65)65 (63; 66)66 (65; 67)64 (63; 65)
Female61 (53; 68)64 (57; 70)64 (59; 68)71 (68; 74)
BMI > 30 (kg/m2)24 (17; 31)26 (19; 33)35 (29; 40)39 (33; 44)
Symptom duration (years), mean14 (12; 16)14 (12; 16)16 (14; 17)13 (12; 15)
Deterioration of symptoms (during last 2 years)64 (55; 73)62 (54; 70)67 (61; 72)50 (44; 55)
WOMAC total, mean43 (39; 46)41 (38; 44)46 (44; 49)36 (34; 38)
WOMAC pain, mean42 (38; 45)43 (39; 46)47 (45; 49)37 (35; 40)
WOMAC function, mean42 (38; 45)40 (36; 43)45 (42; 47)35 (32; 37)
WOMAC stiffness, mean44 (40; 49)45 (42; 49)50 (47; 53)40 (38; 43)
Any impact on personal situation89 (83; 94)72 (64; 79)85 (80; 89)72 (67; 77)
WHO-551 (47; 56)50 (46; 54)48 (45; 51)53 (50; 56)
Orthopaedist is treating68 (60; 77)58 (50; 67)77 (72; 82)68 (63; 73)
Opioid prescriptiona14 (7; 20)13 (8; 19)17 (12; 21)10 (7; 13)
Daily use of medication24 (16; 32)28 (20; 35)27 (22; 33)18 (14; 22)
Physical therapy prescriptiona46 (37; 55)45 (37; 54)51 (45; 57)47 (42; 52)
Patient desiring TJR: knee or hip32 (24; 41)5 (2; 8)28 (22; 33)3 (1; 5)
Having at least one artificial joint36 (27; 45)13 (7; 20)29 (24; 34)11 (7; 14)
  1. Values are percentages unless indicated otherwise. Values in brackets are 95% confidence intervals. a indicates information derived from claims data